Physical and chemical stability of palonosetron HCl with cisplatin,carboplatin,and oxaliplatin during simulated Y-site administration

Abstract

The objective of this study was to evaluate the physical and chemical stability of undiluted palonosetron HCl 50 mcg/mL with cisplatin 0.5 mg/mL, carboplatin 5 mg/mL, and with oxaliplatin 0.5 mg/mL in infusion solutions during simulated Y-site administration.

Triplicate test samples were prepared by admixing 7.5 mL of palonosetron HCl with 7.5 mL of the cisplatin, carboplatin, and oxaliplatin dilutions. Physical stability was assessed using a multistep evaluation procedure that included both turbidimetric and particulate measurement as well as visual inspection. Chemical stability was assessed using stability-indicating HPLC analytical techniques based on the determination of drug concentrations. Evaluations were performed initially upon mixing and 1 and 4 hours after mixing.

The samples were clear and colourless when viewed in normal fluorescent room light and when viewed with a Tyndall beam. Measured turbidity remained unchanged and particulate content was low and exhibited little change. HPLC analysis found palonosetron HCl, cisplatin, carboplatin, and oxaliplatin remained stable throughout the 4-hour test with no drug loss.

Palonosetron HCl is physically compatible and chemically stable with cisplatin, carboplatin, and oxaliplatin during Y-site administration.

Keywords

carboplatin cisplatin compatibility oxaliplatin palonosetron stability

Get full access to this article

View all access options for this article.

References

Aloxi (package insert). Bloomington, Minnesota: MGI PHARMA, INC., July, 2003.

Stacher G. Palonosetron (Helsinn). Curr Opin Investig Drugs 2002; 3: 1502-1507.

Eglen RM , Lee CH , Smith WL , Johnson LG , Clark R , Whiting RL , Hedge SS. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br J Pharmacol 1995; 114: 860-866.

Allen LV Jr , Levinson RS , Phisutsinthrop D. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm 1977; 34: 939-943.

Trissel LA , Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992; 49: 1716-1719.

Trissel LA , Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993; 50: 300-304.

Trissel LA , Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993; 50: 2359-2363.

Palonosetron HCl IV Injection 0.05 mg/mL and 0.15 mg/mL end product test procedure. Minneapolis, Minnesota: MGI PHARMA, Inc., undated.

Zhang YP , Xu QA , Trissel LA , Gilbert DL , Martinez JF. Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions. Ann Pharmacother 1997; 31: 1465-1470.

10.

Jerremalm E , Eksborg S , Ehrsson H. Hydrolysis of oxaliplatin—evaluation of the acid dissociation constant for the oxalato monodentate complex. J Pharm Sci 2003; 92: 436-438.